Helus Pharma Inc. (HELP) stock
Close on Nov 11, 2026Market cap $484.82MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Mar 31, 2026
Valuation
- Market cap
- C$683.89M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Diluted shares
- 35M
Trading
- Previous close
- $9.07
- Open
- $9.26
- Day's range
- $9.20 – $9.83
- Volume
- 1,363,471
- Average volume (20 days)
- 1,462,053
- Beta (5 years)
- 0.89
- RSI (14 days)
- 42.9
- Volatility (1 year)
- 86.3%
- Relative volume
- 0.80×
- WACC
- 9.3%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | HELP | S&P 500 | Difference | HELP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -20.4% | -2.4% | −18.0 pts | ||
| 3 months | -6.9% | -1.2% | −5.8 pts | ||
| Year to date | +14.8% | +12.3% | +2.5 pts | ||
| 1 year | +47.9% | +12.4% | +35.4 pts | ||
| 3 years | -42.3% | +78.8% | −121.1 pts | -16.7% | +21.4% |
| 5 years | -86.9% | +75.2% | −162.0 pts | -33.4% | +11.9% |
Seven years at a glance
Fiscal years 2020 to 2026, CAD
Revenue
Gross profit
EPS, diluted
Free cash flow
Press releases
Releases Helus Pharma filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Helus Pharma
Pharmaceutical Preparations
Cybin Inc. is a Canadian pharmaceutical company that focuses on research and development activities within the pharmaceutical preparations sector. The organization operates through research operations and subsidiary entities, including Helus Pharma, Adelia, Journey, and Serenity. It maintains laboratory equipment, software, and intellectual property portfolios, such as patents and operating rights, to advance its scientific programs. Because the provided corporate records focus on development assets, research expenditures, and laboratory infrastructure rather than commercial sales, specific commercial customers and consumer segments are not detailed.
Company profile, executives and historyHelus Pharma stock: common questions
What is Helus Pharma's stock price?
HELP closed at $9.39 on Nov 11, 2026, up 3.53% on the day.
What is Helus Pharma's market cap?
Helus Pharma was worth $484.82M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
Does Helus Pharma pay a dividend?
No. Helus Pharma has not paid a cash dividend over the last twelve months.
How has HELP stock performed over the past year?
Including dividends, HELP returned +47.9% over the past year, against +12.4% for the S&P 500.
Who are Helus Pharma's competitors?
Companies most similar to Helus Pharma by business, industry and size include NGEN, MSLE, PBM, DRUG, PTCHF.
See a number that looks wrong?